EUVIMEDEUVIMED entdecken
Crossref

Targeting EZH2 to mitigate immune checkpoint resistance in ARID1A-deficient triple-negative breast cancer

Lauren Lukas, Hye Ri Han, Evanthia T. Roussos Torres, Aaron G. Baugh, Oliver Bell, Jason C. Ye, Kenneth Wong, Vyshnavi Pachipulusu, Hualin Zhang, Alan L. Epstein

Advances in Radiotherapy & Nuclear Medicine · 2025

DOI: 10.36922/arnm.5132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Radiotherapy & Nuclear Medicine, 2025. Verfasst von Lauren Lukas und 9 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have shown promise in treating triple-negative breast cancer (TNBC), but resistance to these therapies remains a significant challenge. AT-rich interactive domain 1A (ARID1A), a component of the SWItch/Sucrose Non-Fermentable chromatin remodeling complex, is frequently mutated in TNBC and is associated with increased programmed cell death ligand 1 expression, which contributes to immune evasion. Paradoxically, this mutation may make TNBC potentially more responsive to ICIs. Chromatin-mediated gene expression requires a balance between ARID1A and enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, and ARID1A deficiency results in enhanced EZH2 activity, contributing to various oncologic processes. Epigenetic modulation through EZH2 inhibition could exploit the synthetic lethality between ARID1A deficiency and EZH2 activity, which may reduce the immunosuppressive tumor microenvironment and enhance infiltration and activity of cytotoxic T-cells within the tumor, thereby synergizing with immune checkpoint inhibition. This review explores the potential of EZH2 inhibition as a therapeutic strategy to overcome immune checkpoint resistance in ARID1A-deficient TNBC. In addition, the role of ARID1A deficiency as a radiosensitizer is also discussed in the context of combination therapy strategies.

Zitieren

APA

Lukas, L., Han, H. R., Torres, E. T. R., Baugh, A. G., Bell, O., Ye, J. C., Wong, K., Pachipulusu, V., Zhang, H., & Epstein, A. L. (2025). Targeting EZH2 to mitigate immune checkpoint resistance in ARID1A-deficient triple-negative breast cancer. Advances in Radiotherapy & Nuclear Medicine. https://doi.org/10.36922/arnm.5132

Vancouver

Lukas L, Han HR, Torres ETR, Baugh AG, Bell O, Ye JC, et al. Targeting EZH2 to mitigate immune checkpoint resistance in ARID1A-deficient triple-negative breast cancer. Advances in Radiotherapy & Nuclear Medicine. 2025. doi:10.36922/arnm.5132

BibTeX
@article{Lukas2025,
  author = {Lukas, Lauren and Han, Hye Ri and Torres, Evanthia T. Roussos and Baugh, Aaron G. and Bell, Oliver and Ye, Jason C. and Wong, Kenneth and Pachipulusu, Vyshnavi and Zhang, Hualin and Epstein, Alan L.},
  title = {Targeting EZH2 to mitigate immune checkpoint resistance in ARID1A-deficient triple-negative breast cancer},
  journal = {Advances in Radiotherapy & Nuclear Medicine},
  year = {2025},
  doi = {10.36922/arnm.5132}
}
Kostenlos starten →